Kestra Medical Technologies, a wearable medical device and digital healthcare company, reported impressive financial results for the first quarter fiscal 2026.
Revenue reached $19.4 million, marking a 52% increase compared to the previous year period.
Gross margin expanded to 45.7% in Q1 FY26, a significant improvement from 32.9% in the prior year period.
Revenue Growth
Generated $19.4 million in Q1 FY26, up by 52% from the previous year.
Prescriptions Increase
4,205 prescriptions were written for the ASSURE system, a 51% rise from the prior year period.
Expense Management
GAAP operating expenses were $37.7 million, including $2.9 million of non-recurring new public company costs.
Cash Reserves
Cash and cash equivalents totaled $201.2 million as of July 31, 2025.
Revenue Guidance
Increased FY26 revenue guidance to $88 million, showing a 47% growth compared to FY25.
- The strong revenue growth indicates Kestra's successful commercial momentum in the wearable defibrillator market.
- The expansion of gross margin highlights efficiency improvements and market share gains.
- Operating expenses increased, mainly due to investments in commercial and revenue cycle resources.
- The adjusted EBITDA loss and net loss reflect the company's strategic investments and growth trajectory.
Kestra's first quarter fiscal 2026 results demonstrate solid financial performance and strategic growth initiatives, positioning the company for future success in the digital healthcare sector.